Third Harmonic Bio, Inc.

Third Harmonic Bio, Inc. (THRD) Market Cap

Third Harmonic Bio, Inc. has a market capitalization of $242.8M.

Financials based on reported quarter end 2025-03-31

Price: $5.38

โ–ผ -0.01 (-0.09%)

Market Cap: 242.79M

NASDAQ ยท time unavailable

CEO: Natalie C. Holles

Sector: Healthcare

Industry: Biotechnology

IPO Date: 2022-09-14

Website: https://www.thirdharmonicbio.com

Third Harmonic Bio, Inc. (THRD) - Company Information

Market Cap: 242.79M ยท Sector: Healthcare

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.

Analyst Sentiment

57%
Buy

Based on 5 ratings

Analyst 1Y Forecast: $0.00

Average target (based on 3 sources)

Consensus Price Target

Low

$4

Median

$19

High

$23

Average

$16

Potential Upside: 200.2%

Price & Moving Averages

Loading chart...

Fundamentals Overview

Loading fundamentals overview...

๐Ÿ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-03-31

"Headline metrics (latest quarter ended 2025-03-31): Revenue was ~0 (only ~$48k in the prior 2024-12-31 quarter), and net income was -$15.8M (EPS -0.35). YoY comparisons are directionally negative: net income loss widened vs. the prior-year quarter (2024-03-31 net income -$7.9M โ†’ 2025-03-31 -$15.8M), while sequentially (QoQ) the loss also deepened (2024-12-31 -$13.1M โ†’ 2025-03-31 -$15.8M). Margins were not meaningfully measurable due to near-zero reported revenue. Because THRD appears effectively pre-/near-revenue in this dataset, Revenue and Earnings-based metrics were not applicable for this analysis due to the company's pre-revenue status. The evaluation focused on balance-sheet resilience and cash burn signals instead. Equity remains very large relative to liabilities (~$272.6M equity vs. ~$7.2M liabilities), but total assets have been volatile: assets rose into 2024-09-30/12-31 (~$304.5M/$294.6M) and then declined by 2025-03-31 (~$279.8M). Net debt is negative (net cash) throughout, suggesting liquidity support, though continued net losses imply ongoing burn risk. Total shareholder return cannot be assessed reliably here because marketPerformance price and 1Y/6M/YTD changes are not provided (price shown as 0). Analyst valuation context: consensus target ~$16.15 vs. no usable current price in the feed."

Revenue Growth

Neutral

Reported revenue is effectively near zero across most quarters (0 in 3 of the last 4 quarters; only ~$48k in 2024-12-31). QoQ/YoY revenue growth is not meaningful in this dataset.

Profitability

Neutral

Net losses are persistent and worsening: net income -$15.8M (2025-03-31) vs -$13.1M (2024-12-31) QoQ and vs -$7.9M (2024-03-31) YoY. EPS remains negative; margins cannot be credibly assessed due to negligible revenue.

Cash Flow Quality

Neutral

No cash flow statement is provided. However, continued net losses (-$7.9M to -$15.8M YoY) suggest ongoing cash burn. No dividend payments (yield 0) and no buyback data available.

Leverage & Balance Sheet

Neutral

Balance sheet shows strong equity cushion: equity ~ $272.6M with liabilities ~ $7.2M as of 2025-03-31. Net debt is consistently negative (net cash), reducing leverage risk, though total assets declined from ~$304.5M (2024-09-30) to ~$279.8M (2025-03-31).

Shareholder Returns

Neutral

Total shareholder return cannot be calculated from the provided data (marketPerformance price=0; 1Y/6M/YTD changes are N/A). No dividend yield.

Analyst Sentiment & Valuation

Fair

Consensus price target is $16.15 (median $19), but current price is unavailable in the feed, so upside/downside and implied valuation cannot be quantified.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
๐Ÿ“

SEC Filings (THRD)

ยฉ 2026 Stock Market Info โ€” Third Harmonic Bio, Inc. (THRD) Financial Profile